SlideShare a Scribd company logo
PNEUMONIA
Dr. Sookun Rajeev K
(MD)
Dept of General Medicine
Anna Medical College
Definition:
• Pneumonia is an infection of
the pulmonary parenchyma
(that is; the functional lung
tissue) commonly caused by
infectious agents.
MODE OF TRANSMISSION
Ways you can get pneumonia include:
Bacteria and viruses living in the nose,
sinuses, or mouth may spread to the lungs.
One may breathe some of these germs
directly into your lungs (droplets infection).
Inhalation of food, liquids, vomit, or fluids
from the mouth into the lungs (aspiration
pneumonia).
RISK FACTORS FOR PNEUMONIA
1. Immuno-suppressed patients
2. Cigarette smoking
3. Difficulty in swallowing ( due to
stroke,dementia,parkinson’s
diseases,other neurological conditions)
4. Impaired consciousness (loss of brain
function due to dementia,stroke,etc…)
RISK FACTORS FOR PNEUMONIA
5. Chronic Lung Diseases (COPD,
Bronchiectasis).
6. Frequent suction
7. Medical comorbidities such as Heart
disease, Liver cirrhosis, and Diabetes
8.Recent cold, Laryngitis or flu.
CLASSIFICATION OF PNEUMONIA
According to Area involved:
1. Lobar pneumonia; if one or more lobe is
involved
2. Broncho-pneumonia; the pneumonic
process has originated in one or more
bronchi and extends to the surrounding
lung tissue.
CLASSIFICATION OF PNEUMONIA
According to Area involved:
CLASSIFICATION OF PNEUMONIA
According to Causes:
1. Bacterial (the most common cause of
pneumonia)
2. Viral pneumonia
3. Fungal pneumonia
4. Chemical pneumonia (ingestion of
kerosene or inhalation of irritating
substance)
5. Inhalation pneumonia (aspiration
pneumonia)
CLASSIFICATION OF PNEUMONIA
According to Etiology:
1. Community Acquired Pneumonia
(CAP)
2. Atypical Pneumonia
3. Hospital Acquired Pneumonia
(Nosocomial Pneumonia)
4. Aspiration Pneumonia
5. Opportunistic Pneumonia
COMMUNITY ACQUIRED PNEUMONIA
• This occurs out of hospital or
within 48 h of admission and
may be primary or secondary
to existing disease.
COMMUNITY ACQUIRED PNEUMONIA
Causes include:
 Streptococcus pneumoniae (most
common), Haemophilus influenzae and
Staphylococcus aureus.
Viruses are implicated in approximately
10% of cases.
In pre-existing lung disease (e.g.
COPD/bronchiectasis), organisms such as
Pseudomonas aeruginosa and Moraxella
catarrhalis are more common.
ATYPICAL PNEUMONIA
They can be acquired in the
community or in institutions.
This is caused by organisms
such as Mycoplasma,
Legionella and Chlamydia
species.
HOSPITAL ACQUIRED PNEUMONIA
This is new-onset pneumonia
occurring at or more than 48 h after
admission to hospital.
Gram-negative organisms such as
Pseudomonas and Klebsiella are much
more common causes.
ASPIRATION PNEUMONIA
This occurs as a result of the aspiration of
gastrointestinal contents because of an
inability to protect the airway such as after
a cerebral vascular event or with a
decreased consciousness level.
Anaerobic organisms may be implicated.
Stroke patients are at particular risk of
aspiration pneumonia.
OPPORTUNISTIC PNEUMONIA
• Individuals with cystic fibrosis are at increased
risk of Pseudomonas pneumonia due to changes
in the composition of airway surface mucus.
• Patients with impaired immune system (e.g. HIV+)
are at increased risk of fungal (e.g. Aspergillus),
Pneumocystis jiroveci or viral (e.g. CMV, HSV)
pneumonia.
• Patients on respiratory support (e.g. ventilated in
intensive care) are at increased risk of ventilator-
associated pneumonia (VAP) commonly caused by
Pseudomonas or Klebsiella.
CLINICAL FEATURES OF PNEUMONIA
The ‘typical’ symptoms of pneumonia are:
Fever (rapidly rising 39.5 – 40.5)
Shaking chills
Tachypnoea
Dyspnoea
Productive cough of purulent sputum
Pleuritic chest pain (aggravated by
respiration and coughing)
CLINICAL FEATURES OF PNEUMONIA
The ‘typical’ symptoms of pneumonia are:
Tachypnea – nasal flaring
Pt is very ill and lies on the affected
side to reduce pain
Use of accessory muscles of
respiration
Flushed cheeks
Loss of appetite, lethargy and fatigue
Cyanosed lips and nail beds
CLINICAL FEATURES OF PNEUMONIA
The ‘typical’ symptoms of pneumonia are:
Signs of pulmonary consolidation
(dullness, increased vocal
resonance, bronchial breath
sounds and coarse crepitations)
may be found on physical
examination and coincide with
abnormalities on the CXR.
CLINICAL FEATURES OF PNEUMONIA
The ‘atypical’ symptoms of pneumonia are:
‘Atypical’ pneumonia has a more
gradual onset
Dry cough
Extrapulmonary symptoms
(headache, muscle aching,
fatigue, sore throat, nausea,
vomiting and diarrhoea).
DIAGNOSTICS
• History Taking
• Physical Examination
• Instrumental Diagnostics
PHYSICAL EXAMINATION
Examination may reveal
coarse inspiratory
crepitations.
Bronchial breathing with a
dull percussion note is
present in <25%.
DIAGNOSTICS
1. Chest X-Ray
 Confirm the presence of the diffuse or lobar
pulmonary infiltrates and assess the extent of
infection.
 Air bronchograms may be seen within the areas
of consolidation.
 Other features that may be present include pleural
effusions, pulmonary cavitation or hilar
lymphadenopathy.
 Cavitating lesions may be caused by oral
anaerobic bacteria, enteric Gram-negative bacilli,
S. aureus, Pseudomonas, Legionella, TB and
fungi.
DIAGNOSTICS
1. Chest X-Ray (Lobar)
• Consolidation
confined to
one or more
lobes of the
lungs
DIAGNOSTICS
1. Chest X-Ray (Lobar)
DIAGNOSTICS
1. Chest X-Ray (Bronchopneumonia)
• Patchy
consolidation
usually in the
bases of the
lungs
DIAGNOSTICS
2. Blood tests
1. Full blood count may show a neutrophilia.
2. ABG: assess oxygenation, hypercapnia
and pH.
3. U&Es: raised urea is indicative of
dehydration and is part of the CURB65
score (see later) which assesses severity.
4. Oximetry : Oxygen saturation
DIAGNOSTICS
2. Blood tests
1. C-reactive protein: may be raised and can
help in assessing response to treatment.
2. Blood cultures if pyrexic (and prior to
commencing antibiotic therapy, but should
not delay antibiotics).
3. Serology for atypical organisms should be
taken if clinical suspicion is present and
then repeated in 10-14 days
DIAGNOSTICS
3. Sputum Microscopy and Culture
Sputum microscopy and culture is
important in severe bacterial
pneumonia and those with chronic
lung disease.
DIAGNOSTICS
4. Pleural tap
For pleural effusion, if present and thought
to be parapneumonic, should be aspirated
to assess for infection or empyema and
drained if needed.
Microscopy, culture and sensitivity should
be performed.
 If there is any suggestion there may be a
more sinister cause for the effusion a
sample should be sent for cytology.
DIAGNOSTICS
5.Urine
The urine can be tested for
streptococcal and Legionella
urinary antigen.
These can remain positive even
after antibiotics have been
commenced.
DIAGNOSTICS
6. Bronchoscopy
Fibreoptic bronchoscopy is rarely
performed for pneumonia but has
become the standard invasive
procedure used to obtain lower
respiratory tract secretions from
seriously ill or
immunocompromised patients.
DIAGNOSTICS
6. Bronchoscopy
Samples are collected with a protected
double sheathed brush, by
bronchoalveolar lavage or by
transbronchial biopsy at the site of the
pulmonary consolidation.
It may be indicated too if there is ev-
idence of collapse due to airway
obstruction/ tumour or mucous plug.
ASSESSMENT OF SEVERITY
The management of community
acquired pneumonia is guided by the
severity.
The CURB65 score is a validated tool
to assess severity.
Each component (confusion, urea,
respiratory rate, systolic blood
pressure and age) scores 1 point.
ASSESSMENT OF SEVERITY
A score of 0 or 1 means home
treatment is possible.
A score of 2 warrants hospital
treatment
A score of 3 or above indicates severe
pneumonia requiring admission and
aggressive management.
ASSESSMENT OF SEVERITY
Increasing score is associated with increasing mortality.
Confusion: new confusion,
abbreviated mental test score <8.
Urea >7 mmol/L.
Respiratory rate >30 per min.
Systolic blood pressure <90 mmHg
and/or Diastolic Blood pressure <60
mmHg.
Age >65.
TREATMENT
Mainstay treatment for pneumonia is:
1. Antibiotics
2. O2 (aiming for saturations of 94-
98%)
3. Adequate hydration
4. Analgesia for potential pleuritic
pain
5. Chest physiotherapy
TREATMENT
Community Acquire Pneumonia
(uncomplicated)
• Broad-spectrum penicillin, e.g.
amoxicillin.
Macrolide, e.g. clarithromycin if
penicillin-allergic or if atypical
organism suspected Flucloxacillin if S.
aureus suspected
TREATMENT
Community Acquire Pneumonia (severe)
• Third-generation cephalosporin,
e.g. cefuroxime or co-amoxiclav IV
and macrolide for atypical
organisms Flucloxacillin if S.
aureus suspected
TREATMENT
Atypical Pneumonia
• Erythromycin or other
macrolide Tetracycline for
Chlamydia or Mycoplasma Give
for 10–14 days
TREATMENT
Hospital Acquired Pneumonia
• Broad-spectrum cephalosporin
or co-amoxiclav plus increased
Gram-negative cover, e.g.
aminoglycoside, ciprofloxacin
Vancomycin or teicoplanin if
MRSA pneumonia
TREATMENT
Aspiration Pneumonia
• Cover for anaerobic
organisms Cephalosporin
plus metronidazole
Co-amoxiclav often
sufficient
PROGNOSIS
With treatment, most patients
will improve within 2 weeks
Elderly or very sick patients
may need longer treatment
COMPLICATIONS
Acute Respiratory Distress
Syndrome
Pleural Effusion
Lung Abscess
Respiratory Failure (Requires
mechanical ventilator)
Sepsis, which may lead to organ
failure
16 Pneumonie.pdf

More Related Content

Similar to 16 Pneumonie.pdf

Pneumonia
PneumoniaPneumonia
Pneumonia
Pediatrics
 
Pneumonia
PneumoniaPneumonia
Pneumonia
aswathi c k
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
ami purohit
 
Pneumonia
PneumoniaPneumonia
Pneumonia
Khairul Jessy
 
Pneumonia
PneumoniaPneumonia
Pneumonia
Djlab Alcatraz
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
HariomSuman
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
Yatheendra Vasanth
 
Pneumonia Lecture.pptx
Pneumonia Lecture.pptxPneumonia Lecture.pptx
Pneumonia Lecture.pptx
Platon S Plakar Jr
 
Gwen med surg pneumonia final
Gwen med surg pneumonia finalGwen med surg pneumonia final
Gwen med surg pneumonia final
Gwenneth Zoelie Nongkhlaw
 
PNEUMONIA
PNEUMONIAPNEUMONIA
PNEUMONIA
ANILKUMAR BR
 
Pneumonia
PneumoniaPneumonia
Pneumonia
hemin sab
 
Copy of pneumonia
Copy of pneumoniaCopy of pneumonia
Copy of pneumoniakcmct20
 
Copy of pneumonia
Copy of pneumoniaCopy of pneumonia
Copy of pneumoniakcmct20
 
Pneumonia regi
Pneumonia regiPneumonia regi
Pneumonia regi
Regi Septian
 
Pneumonia / Community Acquired Pneumonia
Pneumonia / Community Acquired Pneumonia Pneumonia / Community Acquired Pneumonia
Pneumonia / Community Acquired Pneumonia
Dr. Pawan Kumar B
 
pneumonia-1.pdf
pneumonia-1.pdfpneumonia-1.pdf
pneumonia-1.pdf
ssuser928abe
 
8 Lower Respiratory Infections
8 Lower Respiratory Infections8 Lower Respiratory Infections
8 Lower Respiratory Infections
Yaser Ammar
 
Pneumonias
PneumoniasPneumonias
Pneumonias
kajal sansoya
 
PNEUMONIA.pptx
PNEUMONIA.pptxPNEUMONIA.pptx
PNEUMONIA.pptx
SaadMohdBello
 
Pneumonia
PneumoniaPneumonia
Pneumonia
Sivendu P
 

Similar to 16 Pneumonie.pdf (20)

Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
Pneumonia Lecture.pptx
Pneumonia Lecture.pptxPneumonia Lecture.pptx
Pneumonia Lecture.pptx
 
Gwen med surg pneumonia final
Gwen med surg pneumonia finalGwen med surg pneumonia final
Gwen med surg pneumonia final
 
PNEUMONIA
PNEUMONIAPNEUMONIA
PNEUMONIA
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Copy of pneumonia
Copy of pneumoniaCopy of pneumonia
Copy of pneumonia
 
Copy of pneumonia
Copy of pneumoniaCopy of pneumonia
Copy of pneumonia
 
Pneumonia regi
Pneumonia regiPneumonia regi
Pneumonia regi
 
Pneumonia / Community Acquired Pneumonia
Pneumonia / Community Acquired Pneumonia Pneumonia / Community Acquired Pneumonia
Pneumonia / Community Acquired Pneumonia
 
pneumonia-1.pdf
pneumonia-1.pdfpneumonia-1.pdf
pneumonia-1.pdf
 
8 Lower Respiratory Infections
8 Lower Respiratory Infections8 Lower Respiratory Infections
8 Lower Respiratory Infections
 
Pneumonias
PneumoniasPneumonias
Pneumonias
 
PNEUMONIA.pptx
PNEUMONIA.pptxPNEUMONIA.pptx
PNEUMONIA.pptx
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 

More from AbdrahmanDOKMAK1

5 Embolie Pulmonaire.pdf
5 Embolie Pulmonaire.pdf5 Embolie Pulmonaire.pdf
5 Embolie Pulmonaire.pdf
AbdrahmanDOKMAK1
 
4 Embolie Pulmonaire.pdf
4 Embolie Pulmonaire.pdf4 Embolie Pulmonaire.pdf
4 Embolie Pulmonaire.pdf
AbdrahmanDOKMAK1
 
downssyndrometrisomy21-120612005049-phpapp02.pdf
downssyndrometrisomy21-120612005049-phpapp02.pdfdownssyndrometrisomy21-120612005049-phpapp02.pdf
downssyndrometrisomy21-120612005049-phpapp02.pdf
AbdrahmanDOKMAK1
 
diphtheria-200216153615.pdf
diphtheria-200216153615.pdfdiphtheria-200216153615.pdf
diphtheria-200216153615.pdf
AbdrahmanDOKMAK1
 
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
AbdrahmanDOKMAK1
 
8 Trois non invasive ventilation.pdf
8 Trois non invasive ventilation.pdf8 Trois non invasive ventilation.pdf
8 Trois non invasive ventilation.pdf
AbdrahmanDOKMAK1
 
hypercalcaemia-111127113054-phpapp02.pdf
hypercalcaemia-111127113054-phpapp02.pdfhypercalcaemia-111127113054-phpapp02.pdf
hypercalcaemia-111127113054-phpapp02.pdf
AbdrahmanDOKMAK1
 
hyperkalemia-160108171542.pdf
hyperkalemia-160108171542.pdfhyperkalemia-160108171542.pdf
hyperkalemia-160108171542.pdf
AbdrahmanDOKMAK1
 
managementoflacticacidosis-140203075122-phpapp01.pdf
managementoflacticacidosis-140203075122-phpapp01.pdfmanagementoflacticacidosis-140203075122-phpapp01.pdf
managementoflacticacidosis-140203075122-phpapp01.pdf
AbdrahmanDOKMAK1
 
Emboliie Pulmonaire.pptx
Emboliie Pulmonaire.pptxEmboliie Pulmonaire.pptx
Emboliie Pulmonaire.pptx
AbdrahmanDOKMAK1
 
asthma-160507070255.pdf
asthma-160507070255.pdfasthma-160507070255.pdf
asthma-160507070255.pdf
AbdrahmanDOKMAK1
 

More from AbdrahmanDOKMAK1 (20)

5 Embolie Pulmonaire.pdf
5 Embolie Pulmonaire.pdf5 Embolie Pulmonaire.pdf
5 Embolie Pulmonaire.pdf
 
4 Embolie Pulmonaire.pdf
4 Embolie Pulmonaire.pdf4 Embolie Pulmonaire.pdf
4 Embolie Pulmonaire.pdf
 
18 Heart EKG.pdf
18 Heart EKG.pdf18 Heart EKG.pdf
18 Heart EKG.pdf
 
downssyndrometrisomy21-120612005049-phpapp02.pdf
downssyndrometrisomy21-120612005049-phpapp02.pdfdownssyndrometrisomy21-120612005049-phpapp02.pdf
downssyndrometrisomy21-120612005049-phpapp02.pdf
 
diphtheria-200216153615.pdf
diphtheria-200216153615.pdfdiphtheria-200216153615.pdf
diphtheria-200216153615.pdf
 
Preeclampsia.pdf
Preeclampsia.pdfPreeclampsia.pdf
Preeclampsia.pdf
 
22 Heart EKG (IDM).pdf
22 Heart EKG (IDM).pdf22 Heart EKG (IDM).pdf
22 Heart EKG (IDM).pdf
 
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
2pj06waht1sezzvi07jh-140623140730-phpapp02.pdf
 
Hypocalcemia.pdf
Hypocalcemia.pdfHypocalcemia.pdf
Hypocalcemia.pdf
 
7 VNI.pdf
7 VNI.pdf7 VNI.pdf
7 VNI.pdf
 
Cours CD.pdf
Cours CD.pdfCours CD.pdf
Cours CD.pdf
 
8 Trois non invasive ventilation.pdf
8 Trois non invasive ventilation.pdf8 Trois non invasive ventilation.pdf
8 Trois non invasive ventilation.pdf
 
hypercalcaemia-111127113054-phpapp02.pdf
hypercalcaemia-111127113054-phpapp02.pdfhypercalcaemia-111127113054-phpapp02.pdf
hypercalcaemia-111127113054-phpapp02.pdf
 
hyperkalemia-160108171542.pdf
hyperkalemia-160108171542.pdfhyperkalemia-160108171542.pdf
hyperkalemia-160108171542.pdf
 
managementoflacticacidosis-140203075122-phpapp01.pdf
managementoflacticacidosis-140203075122-phpapp01.pdfmanagementoflacticacidosis-140203075122-phpapp01.pdf
managementoflacticacidosis-140203075122-phpapp01.pdf
 
Emboliie Pulmonaire.pptx
Emboliie Pulmonaire.pptxEmboliie Pulmonaire.pptx
Emboliie Pulmonaire.pptx
 
Gaz du sang 13-07.pdf
Gaz du sang 13-07.pdfGaz du sang 13-07.pdf
Gaz du sang 13-07.pdf
 
ponction_pleurale.ppt
ponction_pleurale.pptponction_pleurale.ppt
ponction_pleurale.ppt
 
les-etats-de-choc.pdf
les-etats-de-choc.pdfles-etats-de-choc.pdf
les-etats-de-choc.pdf
 
asthma-160507070255.pdf
asthma-160507070255.pdfasthma-160507070255.pdf
asthma-160507070255.pdf
 

Recently uploaded

Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24
Philip Rabenok
 
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
ybout
 
Snam 2023-27 Industrial Plan - Financial Presentation
Snam 2023-27 Industrial Plan - Financial PresentationSnam 2023-27 Industrial Plan - Financial Presentation
Snam 2023-27 Industrial Plan - Financial Presentation
Valentina Ottini
 
Corporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdfCorporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdf
Probe Gold
 
2024-deutsche-bank-global-consumer-conference.pdf
2024-deutsche-bank-global-consumer-conference.pdf2024-deutsche-bank-global-consumer-conference.pdf
2024-deutsche-bank-global-consumer-conference.pdf
Sysco_Investors
 
Investor Day 2024 Presentation Sysco 2024
Investor Day 2024 Presentation Sysco 2024Investor Day 2024 Presentation Sysco 2024
Investor Day 2024 Presentation Sysco 2024
Sysco_Investors
 
cyberagent_For New Investors_EN_240424.pdf
cyberagent_For New Investors_EN_240424.pdfcyberagent_For New Investors_EN_240424.pdf
cyberagent_For New Investors_EN_240424.pdf
CyberAgent, Inc.
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024
CollectiveMining1
 

Recently uploaded (8)

Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24
 
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
 
Snam 2023-27 Industrial Plan - Financial Presentation
Snam 2023-27 Industrial Plan - Financial PresentationSnam 2023-27 Industrial Plan - Financial Presentation
Snam 2023-27 Industrial Plan - Financial Presentation
 
Corporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdfCorporate Presentation Probe June 2024.pdf
Corporate Presentation Probe June 2024.pdf
 
2024-deutsche-bank-global-consumer-conference.pdf
2024-deutsche-bank-global-consumer-conference.pdf2024-deutsche-bank-global-consumer-conference.pdf
2024-deutsche-bank-global-consumer-conference.pdf
 
Investor Day 2024 Presentation Sysco 2024
Investor Day 2024 Presentation Sysco 2024Investor Day 2024 Presentation Sysco 2024
Investor Day 2024 Presentation Sysco 2024
 
cyberagent_For New Investors_EN_240424.pdf
cyberagent_For New Investors_EN_240424.pdfcyberagent_For New Investors_EN_240424.pdf
cyberagent_For New Investors_EN_240424.pdf
 
Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024Collective Mining | Corporate Presentation - May 2024
Collective Mining | Corporate Presentation - May 2024
 

16 Pneumonie.pdf

  • 1. PNEUMONIA Dr. Sookun Rajeev K (MD) Dept of General Medicine Anna Medical College
  • 2. Definition: • Pneumonia is an infection of the pulmonary parenchyma (that is; the functional lung tissue) commonly caused by infectious agents.
  • 3. MODE OF TRANSMISSION Ways you can get pneumonia include: Bacteria and viruses living in the nose, sinuses, or mouth may spread to the lungs. One may breathe some of these germs directly into your lungs (droplets infection). Inhalation of food, liquids, vomit, or fluids from the mouth into the lungs (aspiration pneumonia).
  • 4. RISK FACTORS FOR PNEUMONIA 1. Immuno-suppressed patients 2. Cigarette smoking 3. Difficulty in swallowing ( due to stroke,dementia,parkinson’s diseases,other neurological conditions) 4. Impaired consciousness (loss of brain function due to dementia,stroke,etc…)
  • 5. RISK FACTORS FOR PNEUMONIA 5. Chronic Lung Diseases (COPD, Bronchiectasis). 6. Frequent suction 7. Medical comorbidities such as Heart disease, Liver cirrhosis, and Diabetes 8.Recent cold, Laryngitis or flu.
  • 6. CLASSIFICATION OF PNEUMONIA According to Area involved: 1. Lobar pneumonia; if one or more lobe is involved 2. Broncho-pneumonia; the pneumonic process has originated in one or more bronchi and extends to the surrounding lung tissue.
  • 8. CLASSIFICATION OF PNEUMONIA According to Causes: 1. Bacterial (the most common cause of pneumonia) 2. Viral pneumonia 3. Fungal pneumonia 4. Chemical pneumonia (ingestion of kerosene or inhalation of irritating substance) 5. Inhalation pneumonia (aspiration pneumonia)
  • 9. CLASSIFICATION OF PNEUMONIA According to Etiology: 1. Community Acquired Pneumonia (CAP) 2. Atypical Pneumonia 3. Hospital Acquired Pneumonia (Nosocomial Pneumonia) 4. Aspiration Pneumonia 5. Opportunistic Pneumonia
  • 10. COMMUNITY ACQUIRED PNEUMONIA • This occurs out of hospital or within 48 h of admission and may be primary or secondary to existing disease.
  • 11. COMMUNITY ACQUIRED PNEUMONIA Causes include:  Streptococcus pneumoniae (most common), Haemophilus influenzae and Staphylococcus aureus. Viruses are implicated in approximately 10% of cases. In pre-existing lung disease (e.g. COPD/bronchiectasis), organisms such as Pseudomonas aeruginosa and Moraxella catarrhalis are more common.
  • 12. ATYPICAL PNEUMONIA They can be acquired in the community or in institutions. This is caused by organisms such as Mycoplasma, Legionella and Chlamydia species.
  • 13. HOSPITAL ACQUIRED PNEUMONIA This is new-onset pneumonia occurring at or more than 48 h after admission to hospital. Gram-negative organisms such as Pseudomonas and Klebsiella are much more common causes.
  • 14. ASPIRATION PNEUMONIA This occurs as a result of the aspiration of gastrointestinal contents because of an inability to protect the airway such as after a cerebral vascular event or with a decreased consciousness level. Anaerobic organisms may be implicated. Stroke patients are at particular risk of aspiration pneumonia.
  • 15. OPPORTUNISTIC PNEUMONIA • Individuals with cystic fibrosis are at increased risk of Pseudomonas pneumonia due to changes in the composition of airway surface mucus. • Patients with impaired immune system (e.g. HIV+) are at increased risk of fungal (e.g. Aspergillus), Pneumocystis jiroveci or viral (e.g. CMV, HSV) pneumonia. • Patients on respiratory support (e.g. ventilated in intensive care) are at increased risk of ventilator- associated pneumonia (VAP) commonly caused by Pseudomonas or Klebsiella.
  • 16. CLINICAL FEATURES OF PNEUMONIA The ‘typical’ symptoms of pneumonia are: Fever (rapidly rising 39.5 – 40.5) Shaking chills Tachypnoea Dyspnoea Productive cough of purulent sputum Pleuritic chest pain (aggravated by respiration and coughing)
  • 17. CLINICAL FEATURES OF PNEUMONIA The ‘typical’ symptoms of pneumonia are: Tachypnea – nasal flaring Pt is very ill and lies on the affected side to reduce pain Use of accessory muscles of respiration Flushed cheeks Loss of appetite, lethargy and fatigue Cyanosed lips and nail beds
  • 18. CLINICAL FEATURES OF PNEUMONIA The ‘typical’ symptoms of pneumonia are: Signs of pulmonary consolidation (dullness, increased vocal resonance, bronchial breath sounds and coarse crepitations) may be found on physical examination and coincide with abnormalities on the CXR.
  • 19. CLINICAL FEATURES OF PNEUMONIA The ‘atypical’ symptoms of pneumonia are: ‘Atypical’ pneumonia has a more gradual onset Dry cough Extrapulmonary symptoms (headache, muscle aching, fatigue, sore throat, nausea, vomiting and diarrhoea).
  • 20. DIAGNOSTICS • History Taking • Physical Examination • Instrumental Diagnostics
  • 21. PHYSICAL EXAMINATION Examination may reveal coarse inspiratory crepitations. Bronchial breathing with a dull percussion note is present in <25%.
  • 22. DIAGNOSTICS 1. Chest X-Ray  Confirm the presence of the diffuse or lobar pulmonary infiltrates and assess the extent of infection.  Air bronchograms may be seen within the areas of consolidation.  Other features that may be present include pleural effusions, pulmonary cavitation or hilar lymphadenopathy.  Cavitating lesions may be caused by oral anaerobic bacteria, enteric Gram-negative bacilli, S. aureus, Pseudomonas, Legionella, TB and fungi.
  • 23. DIAGNOSTICS 1. Chest X-Ray (Lobar) • Consolidation confined to one or more lobes of the lungs
  • 25. DIAGNOSTICS 1. Chest X-Ray (Bronchopneumonia) • Patchy consolidation usually in the bases of the lungs
  • 26. DIAGNOSTICS 2. Blood tests 1. Full blood count may show a neutrophilia. 2. ABG: assess oxygenation, hypercapnia and pH. 3. U&Es: raised urea is indicative of dehydration and is part of the CURB65 score (see later) which assesses severity. 4. Oximetry : Oxygen saturation
  • 27. DIAGNOSTICS 2. Blood tests 1. C-reactive protein: may be raised and can help in assessing response to treatment. 2. Blood cultures if pyrexic (and prior to commencing antibiotic therapy, but should not delay antibiotics). 3. Serology for atypical organisms should be taken if clinical suspicion is present and then repeated in 10-14 days
  • 28. DIAGNOSTICS 3. Sputum Microscopy and Culture Sputum microscopy and culture is important in severe bacterial pneumonia and those with chronic lung disease.
  • 29. DIAGNOSTICS 4. Pleural tap For pleural effusion, if present and thought to be parapneumonic, should be aspirated to assess for infection or empyema and drained if needed. Microscopy, culture and sensitivity should be performed.  If there is any suggestion there may be a more sinister cause for the effusion a sample should be sent for cytology.
  • 30. DIAGNOSTICS 5.Urine The urine can be tested for streptococcal and Legionella urinary antigen. These can remain positive even after antibiotics have been commenced.
  • 31. DIAGNOSTICS 6. Bronchoscopy Fibreoptic bronchoscopy is rarely performed for pneumonia but has become the standard invasive procedure used to obtain lower respiratory tract secretions from seriously ill or immunocompromised patients.
  • 32. DIAGNOSTICS 6. Bronchoscopy Samples are collected with a protected double sheathed brush, by bronchoalveolar lavage or by transbronchial biopsy at the site of the pulmonary consolidation. It may be indicated too if there is ev- idence of collapse due to airway obstruction/ tumour or mucous plug.
  • 33. ASSESSMENT OF SEVERITY The management of community acquired pneumonia is guided by the severity. The CURB65 score is a validated tool to assess severity. Each component (confusion, urea, respiratory rate, systolic blood pressure and age) scores 1 point.
  • 34. ASSESSMENT OF SEVERITY A score of 0 or 1 means home treatment is possible. A score of 2 warrants hospital treatment A score of 3 or above indicates severe pneumonia requiring admission and aggressive management.
  • 35. ASSESSMENT OF SEVERITY Increasing score is associated with increasing mortality. Confusion: new confusion, abbreviated mental test score <8. Urea >7 mmol/L. Respiratory rate >30 per min. Systolic blood pressure <90 mmHg and/or Diastolic Blood pressure <60 mmHg. Age >65.
  • 36. TREATMENT Mainstay treatment for pneumonia is: 1. Antibiotics 2. O2 (aiming for saturations of 94- 98%) 3. Adequate hydration 4. Analgesia for potential pleuritic pain 5. Chest physiotherapy
  • 37. TREATMENT Community Acquire Pneumonia (uncomplicated) • Broad-spectrum penicillin, e.g. amoxicillin. Macrolide, e.g. clarithromycin if penicillin-allergic or if atypical organism suspected Flucloxacillin if S. aureus suspected
  • 38. TREATMENT Community Acquire Pneumonia (severe) • Third-generation cephalosporin, e.g. cefuroxime or co-amoxiclav IV and macrolide for atypical organisms Flucloxacillin if S. aureus suspected
  • 39. TREATMENT Atypical Pneumonia • Erythromycin or other macrolide Tetracycline for Chlamydia or Mycoplasma Give for 10–14 days
  • 40. TREATMENT Hospital Acquired Pneumonia • Broad-spectrum cephalosporin or co-amoxiclav plus increased Gram-negative cover, e.g. aminoglycoside, ciprofloxacin Vancomycin or teicoplanin if MRSA pneumonia
  • 41. TREATMENT Aspiration Pneumonia • Cover for anaerobic organisms Cephalosporin plus metronidazole Co-amoxiclav often sufficient
  • 42. PROGNOSIS With treatment, most patients will improve within 2 weeks Elderly or very sick patients may need longer treatment
  • 43. COMPLICATIONS Acute Respiratory Distress Syndrome Pleural Effusion Lung Abscess Respiratory Failure (Requires mechanical ventilator) Sepsis, which may lead to organ failure